Entrada Therapeutics, Inc. (TRDA) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 875K | 1.3M | 1.61M | 1.95M | 20.56M | 37.4M | 19.57M | 94.69M | 59.12M | 41.85M | 43.73M | 18.17M |
| Revenue Growth % | -95.74% | -96.53% | -91.75% | -97.94% | -65.23% | -10.63% | -55.25% | 421.16% | 134.05% | - | - | - |
| Cost of Goods Sold | 805K | 886K | 38.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22.19M | 26.3M |
| COGS % of Revenue | 92% | 68.21% | 2376.77% | - | - | - | - | - | - | - | 50.74% | 144.74% |
| Gross Profit | 70K | 413K | -36.75M | 1.95M | 20.56M | 37.4M | 19.57M | 94.69M | 59.12M | 41.85M | 21.54M | -8.13M |
| Gross Margin % | 8% | 31.79% | -2276.77% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 49.26% | -44.74% |
| Gross Profit Growth % | -99.66% | -98.9% | -287.77% | -97.94% | -65.23% | -10.63% | -9.16% | 1264.75% | 2639.57% | - | - | - |
| Operating Expenses | 42.37M | 42.62M | 10.3M | 48.8M | 42.35M | 43.27M | 41.23M | 41.27M | 38.01M | 36.94M | 7.53M | 8.17M |
| OpEx % of Revenue | 4842.63% | 3281.06% | 638.41% | 2502.51% | 205.99% | 115.69% | 210.67% | 43.58% | 64.29% | 88.28% | 17.22% | 44.96% |
| Selling, General & Admin | 10.12M | 9.55M | 10.3M | 10.92M | 10.27M | 9.86M | 9.97M | 9.24M | 9.4M | 8.65M | 7.53M | 8.17M |
| SG&A % of Revenue | 1157.03% | 735.18% | 638.41% | 560.1% | 49.98% | 26.36% | 50.95% | 9.75% | 15.9% | 20.67% | 17.22% | 44.96% |
| Research & Development | 33.05M | 33.96M | 38.36M | 37.88M | 32.07M | 33.41M | 31.26M | 32.03M | 28.61M | 28.29M | 22.19M | 26.3M |
| R&D % of Revenue | 3777.6% | 2614.09% | 2376.77% | 1942.41% | 156.02% | 89.33% | 159.72% | 33.83% | 48.39% | 67.6% | 50.74% | 144.74% |
| Other Operating Expenses | -805K | -886K | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1000K | -1000K |
| Operating Income | -42.3M | -42.21M | -47.05M | -46.85M | -21.79M | -5.87M | -21.66M | 53.42M | 21.11M | 4.91M | 14.01M | -16.3M |
| Operating Margin % | -4834.63% | -3249.27% | -2915.18% | -2402.51% | -105.99% | -15.69% | -110.67% | 56.42% | 35.71% | 11.72% | 32.04% | -89.7% |
| Operating Income Growth % | -94.14% | -619.41% | -117.25% | -187.69% | -203.21% | -219.61% | -254.57% | 427.77% | 465.28% | 119.18% | 154.03% | 30.88% |
| EBITDA | -41.5M | -44.99M | -45.82M | -45.81M | -20.84M | -4.88M | -20.72M | 54.33M | 22.05M | 5.64M | 14.85M | -15.57M |
| EBITDA Margin % | -4742.63% | -3463.66% | -2838.97% | -2349.49% | -101.39% | -13.04% | -105.88% | 57.38% | 37.29% | 13.48% | 33.95% | -85.69% |
| EBITDA Growth % | -99.09% | -822.93% | -121.13% | -184.32% | -194.54% | -186.42% | -239.57% | 448.98% | 520.82% | 122.52% | 158.4% | 32.66% |
| D&A (Non-Cash Add-back) | 805K | -2.79M | 1.23M | 1.03M | 946K | 992K | 937K | 910K | 934K | 736K | 834K | 730K |
| EBIT | -42.3M | -39.07M | -43.48M | -46.85M | -21.79M | -5.87M | -21.66M | 53.42M | 21.11M | 4.91M | 14.01M | -16.3M |
| Net Interest Income | 0 | 0 | 0 | 3.92M | 4.44M | 5.13M | 5.77M | 4.37M | 4.21M | 4.29M | 4.05M | 4.22M |
| Interest Income | 0 | 0 | 0 | 3.92M | 4.44M | 5.13M | 5.77M | 4.37M | 4.21M | 4.29M | 4.05M | 4.22M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.62M | 3.14M | 3.57M | 3.92M | 4.44M | 5.13M | 5.77M | 4.37M | 4.21M | 4.29M | 38.85M | 4.22M |
| Pretax Income | -39.68M | -39.07M | -43.48M | -42.92M | -17.35M | -739K | -15.89M | 57.79M | 25.33M | 9.2M | 52.86M | -12.08M |
| Pretax Margin % | -4534.74% | -3007.85% | -2693.93% | -2201.28% | -84.39% | -1.98% | -81.21% | 61.03% | 42.84% | 21.98% | 120.86% | -66.49% |
| Income Tax | 38K | 92K | 654K | 178K | 0 | -1.87M | -1.86M | 2.76M | 1.83M | 18.74M | 17.4M | 13.85M |
| Effective Tax Rate % | -0.1% | -0.24% | -1.5% | -0.41% | 0% | 253.04% | 11.7% | 4.77% | 7.23% | 203.77% | 32.91% | -114.62% |
| Net Income | -39.72M | -39.16M | -44.13M | -43.1M | -17.35M | 1.13M | -14.03M | 55.03M | 23.5M | -9.54M | 35.46M | -25.93M |
| Net Margin % | -4539.09% | -3014.93% | -2734.45% | -2210.41% | -84.39% | 3.02% | -71.7% | 58.11% | 39.74% | -22.81% | 81.08% | -142.7% |
| Net Income Growth % | -128.93% | -3562.78% | -214.52% | -178.32% | -173.84% | 111.85% | -139.57% | 312.25% | 452.05% | 61.25% | 241.07% | -11.86% |
| Net Income (Continuing) | -39.72M | -39.16M | -44.13M | -43.1M | -17.35M | 1.13M | -14.03M | 55.03M | 23.5M | -9.54M | 35.46M | -25.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.95 | -0.95 | -1.06 | -1.04 | -0.42 | 0.03 | -0.35 | 1.55 | 0.68 | -0.29 | 1.02 | -0.78 |
| EPS Growth % | -126.19% | -3712.17% | -202.86% | -167.1% | -161.76% | 109.07% | -134.31% | 298.72% | 423.81% | 59.15% | 236% | -8.33% |
| EPS (Basic) | -0.95 | -0.95 | -1.06 | -1.04 | -0.42 | 0.03 | -0.35 | 1.61 | 0.70 | -0.29 | 1.07 | -0.78 |
| Diluted Shares Outstanding | 41.84M | 41.37M | 41.46M | 41.34M | 41.07M | 43.05M | 40.63M | 35.51M | 34.79M | 33.37M | 34.78M | 33.16M |
| Basic Shares Outstanding | 41.84M | 41.37M | 41.46M | 41.34M | 41.07M | 40.84M | 40.63M | 34.18M | 33.5M | 33.37M | 33.28M | 33.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |